InsidersTradesSigma
Follow the Sagent Pharmaceuticals, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 5 January 2016 (Retenue fiscale). Among the most active insiders: Drake Lorin. Every trade is accessible without an account.
Analysts rate Sagent Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Sagent Pharmaceuticals, Inc. is a company that specializes in the manufacturing and distribution of generic pharmaceutical products. It primarily operates in the U.S. market and focuses on injectable medications.